Tharimmune, Inc. (THAR)
NASDAQ: THAR · Real-Time Price · USD
3.090
-0.100 (-3.13%)
At close: Jan 6, 2026, 4:00 PM EST
3.170
+0.080 (2.59%)
After-hours: Jan 6, 2026, 7:54 PM EST
Tharimmune Employees
As of December 31, 2024, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,439,748
Market Cap
108.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
THAR News
- 19 days ago - Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network - PRNewsWire
- 25 days ago - Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy - Business Wire
- 7 weeks ago - Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids - PRNewsWire
- 2 months ago - Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy - PRNewsWire
- 2 months ago - Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy - PRNewsWire
- 4 months ago - Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl - GlobeNewsWire
- 4 months ago - Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments - Accesswire
- 5 months ago - Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl - Accesswire